Free Trial

Arcellx (ACLX) Stock Price, News & Analysis

Arcellx logo
$62.46 -4.77 (-7.09%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Arcellx Stock (NASDAQ:ACLX)

Key Stats

Today's Range
$61.09
$64.73
50-Day Range
$60.26
$72.74
52-Week Range
$47.88
$107.37
Volume
402,668 shs
Average Volume
541,553 shs
Market Capitalization
$3.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$108.46
Consensus Rating
Buy

Company Overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Remove Ads

Arcellx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

ACLX MarketRank™: 

Arcellx scored higher than 41% of companies evaluated by MarketBeat, and ranked 661st out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcellx has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 13 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arcellx has received no research coverage in the past 90 days.

  • Read more about Arcellx's stock forecast and price target.
  • Earnings Growth

    Earnings for Arcellx are expected to decrease in the coming year, from ($1.58) to ($2.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcellx is -89.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcellx is -89.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcellx has a P/B Ratio of 6.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arcellx's valuation and earnings.
  • Percentage of Shares Shorted

    17.49% of the float of Arcellx has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcellx has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcellx has recently decreased by 1.54%, indicating that investor sentiment is improving.
  • Dividend Yield

    Arcellx does not currently pay a dividend.

  • Dividend Growth

    Arcellx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.49% of the float of Arcellx has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcellx has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcellx has recently decreased by 1.54%, indicating that investor sentiment is improving.
  • News Sentiment

    Arcellx has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Arcellx this week, compared to 5 articles on an average week.
  • Search Interest

    22 people have searched for ACLX on MarketBeat in the last 30 days. This is an increase of 69% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Arcellx to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,181,646.00 in company stock.

  • Percentage Held by Insiders

    Only 6.24% of the stock of Arcellx is held by insiders.

  • Percentage Held by Institutions

    96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcellx's insider trading history.
Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Stock News Headlines

New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Arcellx Impressive Safety Data Leaves Doubts
ACLX June 20th Options Begin Trading
Stifel Nicolaus Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Evercore ISI Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
See More Headlines

ACLX Stock Analysis - Frequently Asked Questions

Arcellx's stock was trading at $76.69 on January 1st, 2025. Since then, ACLX shares have decreased by 17.3% and is now trading at $63.43.
View the best growth stocks for 2025 here
.

Arcellx, Inc. (NASDAQ:ACLX) announced its earnings results on Thursday, February, 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.24. The firm earned $15.27 million during the quarter, compared to analysts' expectations of $27.42 million. Arcellx had a negative net margin of 25.94% and a negative trailing twelve-month return on equity of 8.28%.

Arcellx (ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcellx investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
2/27/2025
Today
4/03/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACLX
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$108.46
High Stock Price Target
$136.00
Low Stock Price Target
$82.00
Potential Upside/Downside
+61.3%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-70,690,000.00
Pretax Margin
-25.18%

Debt

Sales & Book Value

Annual Sales
$107.94 million
Price / Cash Flow
N/A
Book Value
$9.97 per share
Price / Book
6.74

Miscellaneous

Free Float
50,701,000
Market Cap
$3.69 billion
Optionable
Optionable
Beta
0.32
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ACLX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners